Loading…
Loading…
Loading…
Semaglutide
Wegovy tablets contain semaglutide, a prescription-only medicine used for weight loss and weight maintenance alongside a reduced-calorie meal plan and increased physical activity. The licensed use described in the UK product information is for adults with obesity, or adults who are overweight and have at least one weight-related health problem. Semaglutide is similar to a natural hormone called GLP-1. It acts on areas of the brain involved in appetite regulation, which can help a person feel fuller, less hungry and experience fewer food cravings. Wegovy tablets are taken once daily and are available in four strengths. A qualified prescriber must assess whether any treatment option is clinically appropriate after a suitable consultation and verification process. This page provides general patient information only. It is not a diagnosis, treatment recommendation, product offer or guarantee that Wegovy will be prescribed.

| Dosage | Price |
|---|---|
| 1.5 mg | £140 |
| 4mg | £165 |
| 9 mg | £175 |
| 25mg | £179 |
Active Ingredient
Semaglutide
Brand
Novo Nordisk Limited
Drug Class
GLP-1 receptor agonist
Administration
Once-daily oral tablet. Take only as prescribed and follow the current Patient Information Leaflet.
Prescription Status
Prescription-only medicine
Dosage Form
Tablet for oral use
Strengths Available
1.5 mg, 4 mg, 9 mg, 25 mg
In OASIS 4, a 64-week randomised trial in adults with obesity, or overweight with at least one weight-related comorbidity, the full-analysis-set mean change in body weight was -13.6% with semaglutide 25 mg tablets and -2.2% with placebo. All participants followed a reduced-calorie diet and increased physical activity.
This is a group-level trial result, not a prediction or guarantee for an individual. In the same analysis, 18% of people randomised to oral semaglutide permanently discontinued randomised treatment during the trial. Results and tolerability vary.
Duration & Size
64-week, phase 3b, double-blind randomised placebo-controlled trial involving 307 adults. Of these, 205 were randomised to oral semaglutide and 102 to placebo.
Highest Avg Weight Loss
The full-analysis-set mean change from baseline at week 64 was -13.6% with semaglutide 25 mg tablets and -2.2% with placebo. A separate estimand assuming patients remained on treatment and did not receive additional anti-obesity therapies was -16.6% and -2.8%, respectively.
Common Side Effects
Nausea, Vomiting, Diarrhoea, Constipation, Stomach pain, Indigestion
Key Takeaway
The labelled trial found greater group-level weight loss with oral semaglutide than placebo when used with a reduced-calorie diet and increased physical activity. It does not establish an expected outcome for every person.
Take Wegovy tablets only as prescribed. The current UK product information describes a gradual dose escalation to help support tolerability. The prescriber confirms the appropriate dose and whether any change is suitable.
| Weeks | Dose | Frequency |
|---|---|---|
| At least 1 month | 1.5 mg | Once daily |
| At least 1 month | 4 mg | Once daily |
| At least 1 month | 9 mg | Once daily |
| Maintenance dose | 25 mg | Once daily |
Important: Take the tablet on an empty stomach after fasting for at least 8 hours. Swallow it whole with a sip of water, up to 120 mL. Do not split, crush or chew it. Wait at least 30 minutes before eating, drinking or taking other oral medicines. If a dose is missed, the PIL says to skip it and take the next dose on the following day. Do not change the dose, combine with another GLP-1 receptor agonist or stop treatment without speaking to a healthcare professional.
There is no guaranteed timeframe for an individual result. In OASIS 4, weight loss occurred early and continued during the 64-week trial. Individual response and tolerability vary, so progress should be reviewed with the prescriber.
The current UK Patient Information Leaflet identifies Novo Nordisk Limited as the company for Wegovy tablets. Product information should be checked against the latest UK PIL and Summary of Product Characteristics before publication or clinical use.
Access to any prescription treatment requires a suitable assessment by an authorised prescriber. For an online weight-management service, the assessment should include timely two-way communication and independent verification of relevant information rather than relying on a questionnaire alone.
The MHRA announcement stated that Wegovy tablets were not available through the NHS at the time of its publication on 11 June 2026. NHS availability may change and should be checked against current NHS and NICE information before making a current-access claim.
The supplied UK regulatory sources do not provide a public roll-out timetable. This page does not confirm current stock, private availability, price or delivery.
Not applicable. Wegovy tablets are taken by mouth and should not be injected.
Not applicable. Wegovy tablets are taken by mouth and should not be injected.
Not applicable. Wegovy tablets are taken by mouth and should not be injected.
The PIL lists headache, nausea, vomiting, diarrhoea, constipation, stomach pain, tiredness and indigestion as very common side effects. It states that these effects usually go away over time. Other common effects include dizziness, burping, flatulence, bloating, gastritis, reflux or heartburn, gallstones, hair loss, change in taste, altered skin sensation and low blood sugar in people with diabetes.
Serious side effects are extremely rare, but it is important to know the signs so you can get help if you need it.
ⓘAcute pancreatitis
Seek urgent medical help for severe, persistent stomach pain, with or without nausea and vomiting. The PIL states that this can be a sign of acute pancreatitis.
ⓘSevere allergic reaction
Seek immediate medical help for breathing problems, swelling of the face, lips, tongue or throat with difficulty swallowing, wheezing, fast heartbeat, pale and cold skin, dizziness or weakness.
ⓘSudden or worsening eyesight changes
Urgently contact a doctor if there is sudden loss of vision or rapidly worsening eyesight. The PIL identifies a very rare eye condition called non-arteritic anterior ischaemic optic neuropathy, also known as NAION.
ⓘBowel obstruction
A severe form of constipation with symptoms such as stomach ache, bloating and vomiting is listed as a side effect with frequency not known. Seek medical advice promptly if worried.
ⓘComplications of diabetic eye disease
If you have diabetes, tell your doctor about eye problems or changes in vision during treatment.
ⓘKidney or bladder stones
Signs listed in the PIL include back or lower abdominal pain, difficulty urinating or a change in urine colour. Speak to a healthcare professional if these occur.
Not applicable. Wegovy tablets are an oral medicine.
The PIL states that very common gastrointestinal effects usually go away over time. The duration of individual side effects varies.
This page does not provide a simplified long-term safety prediction. Current warnings, contraindications and monitoring requirements should be checked in the latest UK Patient Information Leaflet and Summary of Product Characteristics.
Trial results do not predict an individual's rate of weight change. Contact the prescriber if you have concerns about weight change, food intake, hydration or side effects.
Keep out of the sight and reach of children. Store in the original package to protect from light and moisture. The PIL states that no special temperature storage conditions are required. Do not use after the expiry date on the blister and carton.
The supplied PIL does not provide specific travel advice. Keep the medicine in its original package and ask a pharmacist for advice before travelling if you are unsure about storage, timing or carrying medicines.
Risk: The supplied UK PIL and SmPC do not provide a medicine-specific claim about muscle-mass preservation or loss for this page.
Advice: Do not rely on unsourced supplement, diet or exercise claims. Discuss nutrition, activity and any concerns about strength or body composition with an appropriate healthcare professional.
Common questions about the product. If you have more questions, please contact our support team or book a consultation with one of our clinicians.
This is general patient information for an approved inner information page. It is not a diagnosis, medical advice, treatment recommendation, product offer or guarantee that Wegovy tablets will be prescribed. A qualified prescriber must decide whether any treatment option is clinically appropriate after a suitable consultation and verification process. Always read the current Patient Information Leaflet. Report suspected side effects to a doctor, pharmacist or nurse and consider reporting them through the MHRA Yellow Card Scheme.
MHRA announcement published 11 June 2026. Used for UK authorisation status, POM status, labelled adult population, administration context, NHS status at publication and Yellow Card signposting.
https://www.gov.uk/government/news/first-glp-1-tablet-for-weight-loss-approved-in-the-ukUK PIL last updated 16 June 2026. Used for patient-facing product description, strengths, administration, warnings, side effects, pregnancy and breastfeeding information, storage and Yellow Card reporting.
https://www.medicines.org.uk/emc/product/102344/pilUK SmPC last updated 16 June 2026. Used for the authorised indication, labelled dosing schedule, warnings and OASIS 4 trial data. Check the current SmPC before publication because product information can change.
https://www.medicines.org.uk/emc/product/102347/smpcGPhC guidance used for online-service safeguards, including two-way consultation, independent verification and identity checks.
https://www.pharmacyregulation.org/pharmacies/standards-and-guidance-registered-pharmacies/providing-weight-management-services-faqsOfficial UK route for reporting suspected side effects.
https://yellowcard.mhra.gov.uk/The information on this page is based on the sources listed above. Always consult with a qualified healthcare professional for medical advice.